T he viral mitochondrial inhibitor of apoptosis vMIA is encoded by human cytomegalovirus (CMV) and closely related primate CMVs (1, 2) , and appears to be unique: no overt homologues of this gene have been found to date in any other viral or cellular genome, including those of other CMVs and other herpesviruses. The antiapoptotic function of vMIA seems to play a critical role in replication of human and primate CMVs (reviewed in refs. [1] [2] [3] . vMIA is predominantly localized at mitochondria, and blocks the Fas-mediated apoptotic pathway downstream of caspase-8 activation and conversion of Bid into tBid, but upstream of mitochondrial permeabilization (1), i.e., at or close to the step suppressed by Bcl-2 (4, 5) . The amino acid sequence of vMIA lacks any homology with Bcl-2, suggesting that the mechanisms of action of these two proteins differ. The first functional evidence favoring this notion was gained in experiments with mitochondtria isolated from HeLa cells stably transfected with either Bcl-2, Bcl-X L , or vMIA (3). These mitochondria were resistant to GST-tBid-mediated cytochrome c release, compared to control mitochondria, but to a different degree. Although Bcl-2-or Bcl-x L -containing mitochondria became permeable when exposed to an excess of tBid, vMIA-containing mitochondria remained intact even in the presence of a high concentration of tBid. This behavior of Bcl-2-and of Bcl-x Lcontaining mitochondria is consistent with the notion that Bcl-2 blocks apoptosis, at least in part, through its association with tBid or with another BH3-only death-activating factor (6) (7) (8) , and, apparently, not through direct association with Bax or Bak: (i) Bcl-2 does not associate with Bax in the absence of Triton X-100 (9, 10); (ii) Bcl-2 and Bcl-x L mutants that lack affinity to Bax retain their cell-death-suppressing activity (11) (12) (13) (14) ; and (iii) Bcl-2 or Bcl-x L localize at mitochondria of cells transfected with these genes, but this does not affect the cytoplasmic distribution of GFP-Bax in these cells (15) .
The insensitivity of vMIA-containing mitochondria to GST-tBid suggested that vMIA suppresses mitochondrial permeabilization not through sequestration of tBid, but, perhaps, through an interaction with another protein. Previously, we reported that vMIA contains two amino acid segments that are necessary and sufficient for its antiapoptotic function, Tyr-5-Leu-34, which targets vMIA to mitochondria, and Asn-115-Arg-147 with an as-yet-unidentified function (16) . Our experiments reported here reveal the function of this domain and the mechanism of action of vMIA. Proteins and Plasmids. Full-length oligomeric recombinant Bax and monomeric recombinant Bax were described elsewhere (19, 20) . Recombinant tBid was purchased from R & D Systems. GSTtBid͞pGEX-4T-1 expression plasmid was a generous gift of Eric A. Hendrickson (Brown University, Providence, RI). N-biotinylated synthetic peptides vMIA and vMIA E128P (Ͼ95% purity grade) were made at BioSynthesis (Lewisville, TX). Mammalian expression plasmids (based on pcDNA3) encoding vMIA and its deletion mutants were described elsewhere (1, 16) , except for pcDNA3vMIAE128P that was constructed by side-directed mutagenesis of pcDNA3vMIAmyc. Anti-adenine nucleotide translocator (ANT) antiserum (21) was generously provided by Patricia Schmid (University of Minnesota, Austin).
Experimental Procedures
Immunoprecipitations, Immunocytochemistry, Subcellular Fractionation, in Vitro Assay for the Efflux of Cytochrome c, Smac͞Diablo, and HtrA2͞Omi, and in Vitro Binding Assays. These experiments were performed as described (1, 22, 23) . Detailed protocols are in Supporting Text, which is published as supporting information on the PNAS web site. For immunohistochemical detection of nontagged vMIA and endogenous Bax, MRC-5 fibroblasts infected with human CMV were stained with rabbit anti-vMIA antiserum (1) and murine monoclonal anti-Bax (BD Biosciences Pharmingen, clone 3).
Results
Bax but Not Bak Coimmunoprecipitates with vMIA from Cell Lysates.
In an effort to reveal the mechanism of the antiapoptotic function of vMIA, we immunoprecipitated vMIA from lysates of HeLa cells stably transfected with vMIA, and examined these immunoprecipitates for the presence of various apoptosis-related proteins by immunoblotting. These experiments revealed that Bax coprecipitates with vMIA (Fig. 1A) . We obtained similar results with lysates of a number of other cells, BJAB cells stably transfected with vMIA, and HeLa, HCT116, and Cos-7 cells transiently transfected with vMIA (data not shown). We also tested whether vMIA binds Bak, a close structural and functional homologue of Bax (24, 25) . These experiments were done in a fashion similar to the experiments shown in Fig. 1 A, transfected with GFP-Bax, cultured for 24 h, fixed, stained with anti-myc to visualize vMIA, and examined under a confocal microscope (Fig. 1C) . Bax (green fluorescence) was, as reported (15), diffusely distributed throughout the cytoplasm of cells that did not express vMIA (red fluorescence), but colocalized (as indicated by yellow in the overlay) with vMIA, which associates with mitochondria, as confirmed by its colocalization with mitochondrial markers (1). Similar results were obtained with HeLa, HCT116, and Baxdeficient HCT116 BaxϪ/Ϫ cells transiently cotransfected with vMIA and GFP-Bax (not shown) and with human fibroblasts infected with human CMV (Fig. 1C) . Examination of subcellular fractions from HeLa͞vMIA cells and from human fibroblasts infected with human CMV (Fig. 1D) for the presence of endogenous Bax confirmed that, in vMIA-expressing transfected or CMV-infected cells, Bax was mainly associated with the mitochondrial fraction, whereas in control cells, Bax was mostly cytoplasmic. vMIA transiently transfected into Bax-deficient HCT116 BaxϪ/Ϫ cells was predominantly localized at mitochondria (immunofluorescence observations, data not shown), demonstrating that mitochondrial targeting of vMIA does not require the presence of Bax.
Bax-Binding Domain of vMIA Is Required but Is Not Sufficient for its
Cell-Death-Suppressing Activity. To identify the Bax-binding domain of vMIA, we transiently transfected Cos-7 cells and HeLa cells with various deletion mutants of vMIA (all myc-tagged), and examined the affinity of these mutants to Bax in a coimmunoprecipitation assay similar to that shown in Fig. 1 A. A summary of these experiments is shown in Table 1 . Bax coimmunoprecipitated with vMIA⌬35-112͞⌬148-163, consisting essentially of only the two segments required for its antiapoptotic activity, and vMIA⌬2-23 and vMIA⌬23-34, both with an inactivating deletion in the mitochondria-targeting domain (16) , but failed to coimmunoprecipitate with vMIA⌬31-163, vMIA⌬115-130, vMIA⌬131-147, and the point mutant vMIAE128P, each containing a functional mitochondrial targeting domain and either completely lacking or containing a mutation in vMIA's Asn-115-Arg-147 segment, which abolished its cell-death suppressing function (Table 1 ). These observations demonstrated that the Asn-115-Arg-147 segment of vMIA (or most of it) is required for the ability of vMIA to bind Bax. Furthermore, vMIA⌬2-23 and vMIA⌬23-34 retained Bax-binding function, indicating that (i) the mitochondria-targeting domain is not required for this interaction, and, therefore, the Asn-115-Arg-147 segment of vMIA is solely responsible for Bax binding, and (ii) association of Bax with mitochondria-targeting signal-deficient vMIA mutants does not suppress its proapoptotic activity.
Previously, we found that vMIA coprecipitates mitochondrial ANT (1) . We tested the immunoprecipitates of various vMIA mutants in Cos-7 cells on the presence of ANT by immunoblotting with anti-ANT, and found that the cell-death-suppressing activity of vMIA mutants did not correlate with their ability to pull down ANT from the cell lysates. vMIA, ⌬2-23 (mitochondrial targeting deficient), ⌬115-130 and ⌬131-147 (both Bax binding deficient) pulled down ANT, whereas ⌬35-112͞⌬148-163 (a functional mini-vMIA protein containing both domains), ⌬23-34 (mitochondrial targeting deficient), and ⌬131-147 (mitochondrial targeting only) did not. Thus, there appeared to be no definitive segment of vMIA responsible for its association with ANT, suggesting that this interaction is likely of a nonspecific nature.
To examine whether vMIA binds Bax directly or through an intermediary, we tested the affinity of a synthetic N-biotinylated peptide with the amino acid sequence of the Val-114-Ala-150 segment of vMIA (denoted below as vMIA ) to a bacterially produced recombinant Bax. After incubation with Bax, vMIA was pulled down with streptavidin-agarose beads, and the polypeptides associated with the beads were then separated by SDS͞PAGE and examined by immunoblotting (Bax) or with horseradish peroxidase-streptavidin (vMIA ). N-biotinylated peptide with a sequence identical to that of vMIA 114-150 except for the substitution of a conserved (2) residue E128P to P (vMIA 114-150 E128P) was used as a control based on the inability of vMIAE128P to bind Bax or to protect cells from apoptosis (Table 1) . Bax bound to vMIA 114-150 , but not to vMIA 114-150 E128P ( Fig. 2A) , confirming that (i) vMIA binds Bax, (ii) the interaction between the two proteins is direct and does not require any intermediary (although it does not rule out that the intracellular vMIA-Bax complex contains other proteins as well), and (iii) Bax-binding domain of vMIA is confined within its Val-114-Ala-150 segment. A shorter N-biotinylated synthetic peptide with a sequence corresponding to the vMIA 114-141 segment failed to bind Bax in similar experiments (data not shown), suggesting that at least some of the extra amino acids in vMIA are required for its Bax-binding function. We also tested whether vMIA binds either Bax or Bak present in mitochondria isolated from HeLa cells. Purified mitochondria were incubated at 37°C for 30 min with vMIA , vMIA E128P, or buffer alone, then washed, lysed, and pulled down with streptavidin beads. The proteins on the beads were then separated by SDS͞PAGE and analyzed by Western blotting for the presence of Bax or Bak. As shown in Fig. 2B , Bax selectively associated with vMIA 114-150 , whereas we could not detect any vMIA-selective association of Bak to the beads in excess of nonspecific binding.
vMIA Does Not Prevent Binding of tBid to Bax. After exposure to tBid, Bax and Bak undergo a conformational change, oligomerize, and then trigger the efflux of mitochondrial death-activating factors into the cytoplasm (28, 29) . vMIA blocks mitochondrial membrane permeabilization and suppresses apoptosis in HeLa and HCT116 cells (Figs. 5 and 6A , which are published as supporting information on the PNAS web site). We set out to examine whether vMIA interferes with these phenomena in a cell-free environment. It had been shown that mitochondria isolated from HeLa cells contain loosely associated monomeric (nonactivated) Bax (30) . First, we tested whether Bax associated with vMIA-containing mitochondria could bind tBid. We incubated purified mitochondria from HeLa͞ vMIA cells with recombinant tBid, then extensively washed the mitochondria, lysed them in a Triton X-100-containing buffer, immunoprecipitated vMIA with anti-myc, and tested the immunoprecipitates for the presence of Bax and tBid by Western blotting. We found (Fig. 2C) that, under these cell-free conditions, tBid coimmunoprecipitated with vMIA and Bax, presumably via its binding to Bax. To establish in a better-defined system if vMIA competes with tBid for Bax binding, we examined whether GSTtBid bound Bax in the presence of an excess of vMIA , using GST and vMIA E128P as controls. Upon mixing and incubating the reagents, GST-tBid (or GST) was immunoprecipitated with anti-GST, then the proteins associated with the immunoprecipitates were separated by SDS͞PAGE, and examined for the presence of Bax, the vMIA peptides, and GST-tBid or GST (Fig.  2D ). Bax associated with GST-tBid, but not with GST. vMIA associated with the GST-tBid͞Bax complex, but not with GSTtBid in the absence of Bax. vMIA E128P did not associate with the GST-tBid͞Bax complex. Importantly, even a 10-fold molar excess of vMIA failed to prevent GST-tBid͞Bax association, even though all Bax molecules were associated with vMIA (Fig.  2E) . Thus, there is no competition between GST-tBid and vMIA for Bax, and GST-tBid does not directly interact with vMIA .
An Excess of Activated Bax, but Not of tBid, Induces Permeabilization
of Mitochondria Isolated from vMIA-Expressing Cells. If vMIA protects mitochondria by directly interacting with and sequestering all intracellular Bax, then it could be expected that the protection by vMIA would not be overcome by an excess tBid, but could be overcome by an excess of activated Bax. To test this hypothesis, we incubated mitochondria isolated from either HeLa͞vMIA cells or control HeLa͞pcDNA3 cells with increasing concentrations of either tBid or oligomeric activated Bax (which had been described in ref. 19 ). We used the efflux of the three mitochondrial deathactivating factors, HtrA2͞Omi, Smac͞Diablo, and cytochrome c, from mitochondria (pellet) into the buffer (supernatant) as an index of mitochondrial membrane permeabilization. Although down with streptavidin-agarose, separated by SDS͞PAGE, and analyzed by Western blotting. As a control, ''input'' represents 2% of the starting material. (C) vMIA does not prevent the binding of tBid to Bax. Isolated mitochondria from HeLa͞vMIA (vMIA mitochondria) (500 g) or from HeLa͞pcDNA3 (500 g) were incubated with tBid (100 nM) or buffer alone, then vMIA was immunoprecipitated (IP) with anti-myc by using an irrelevant antibody as a control, the samples were separated by SDS͞PAGE, and Bax, tBid, and vMIA were then detected by Western blotting (WB). Asterisk indicates a band that may be either of a nonspecific nature, or a covalently modified form of Bax or tBid. As a control, ''input'' represents 2% of the starting material. (D) Recombinant Bax (100 nM) was incubated with GST-tBid (100 nM) in the presence or absence of a 10-fold molar excess of vMIA 114-150 or vMIA 114-150 E128P (each at 1 M), then GST-tBid was immunoprecipitated (IP) with an anti-GST, and bound proteins were separated by SDS͞PAGE and detected by Western blotting (Left). In control samples, Bax (100 nM) was incubated with GST (100 nM) in the presence or absence of the biotinylated peptides (1 M), and GST-tBid was incubated with the biotinylated peptides (1 M) to see whether they bind GST-tBid (Right). (E) Mitochondria isolated from HeLa͞pcDNA3 were incubated either with vMIA 114-150 (1 M) or vMIA 114-150 E128P (1 M) as a control. Peptides were pulled down as in B, then Bax was immunoprecipitated (IP) from the remaining supernatant of the mitochondrial lysate, and the immunoprecipitate was examined for the presence of Bax. An irrelevant antibody was used as a control.
control mitochondria were sensitive to the permeabilizing effect of as little as 0.1 nM tBid, vMIA-containing mitochondria remained essentially intact after being exposed to up to 100 nM tBid, the highest concentration tested, with only a minor leakage (Fig. 3A) . In contrast, vMIA-containing mitochondria were nearly as sensitive as the control mitochondria in the presence of oligomeric Bax (Fig.  3B) . Monomeric Bax activated with tBid (28) was similar to oligomeric activated Bax in that it also overcame the protective effect of vMIA (Fig. 7A , which is published as supporting information on the PNAS web site). We also examined whether vMIA could protect mitochondria from the permeabilizing effect of tBid. Mitochondria that were isolated from HeLa cells were exposed to vMIA , then to tBid, and examined as above. vMIA was unable to prevent mitochondrial membrane permeabilization (Fig. 7B) , even though all Bax associated with mitochondria was bound to this peptide (Fig. 2E) . BaxϪ/Ϫ cells were intact after an exposure to as high as 100 nM tBid, the highest concentration tested.
Discussion
Here we present evidence that vMIA suppresses the mitochondrial apoptotic signaling pathway by directly binding Bax and sequestering it at mitochondria. In agreement with this mechanism, and within a model (28, 37) that tBid induces mitochondrial membrane permeabilization by activating Bax, mitochondria isolated from vMIA-expressing cells are refractory to the permeabilizing effect of even a vast excess of tBid, but not activated Bax.
vMIA appears to have a dual mitochondria͞endoplasmic reticulum (ER) localization signal, and a significant fraction of the intracellular pool of vMIA is localized at the ER (16, 38) . The deletion mutants vMIA⌬2-23 and vMIA⌬23-34 are not colocalized with mitochondria, and are found in the cytoplasm and in the cytoplasm and at the ER, respectively (1, 38) . These mutants bind Bax but fail to suppress apoptosis. Similarly, a deletion mutant lacking the mitochondria-targeting domain altogether, vMIA 114-150 , binds Bax but fails to prevent tBid-mediated permeabilization of mitochondria in a cell-free assay. These data suggest that mitochondrial targeting of vMIA-associated Bax is required for its sequestration, although the reason for this requirement is, at present, unclear. Our finding that vMIA associates with mitochondria (most likely with the mitochondrial outer membrane, ref. 1) irrespective of the presence or absence of Bax is consistent with the model in which Bax-vMIA complex is attached to mitochondria, at least in part, via the mitochondria-targeting domain of vMIA. It remains to be elucidated whether the mitochondrial localization signal of Bax is involved as well.
Vieira et al. reported (39) that vMIA did not protect intact cells or isolated mitochondria from the damage induced by peptides containing either a Bax-BH3 or Bcl-2-BH3 sequence. This property of the peptides is phenomenologically similar to the effect of recombinant activated Bax on cell-free mitochondria, but different from that of recombinant tBid. At present, the molecular mechanism of Bax-mediated permeabilization of mitochondrial membranes is not known, and it is not clear whether Bax and the peptides act in a similar manner (6) .
Recent data suggest that cells can be divided into at least two distinct phenotypes in regard to the relative contribution of Bax and Bak into the mediation of the mitochondrial apoptotic signaling pathway, those where this pathway is dominated mainly by Bax (Bax D phenotype), and those in which either Bax or Bax can mediate this pathway (Bax͞Bak-codominance, Bax͞Bak coD ). Human colorectal carcinoma HCT116 cells that express both Bax and Bak, represent an example of Bax The apparent inability of vMIA to suppress apoptosis in cells with active Bak suggests that vMIA may be used as a probe to reveal the Bax D phenotype. Ectopic vMIA is functional as a cell death suppressor in several cell types, including HeLa (1), HCT116 (this study), and Cos-7 and MRC5 normal human fibroblasts (L.M.B. and V.S.G., unpublished observations). Interestingly, human and primate CMV encode vMIA (2), suggesting that cell types that are essential for supporting CMV infections in humans and primates may be of the Bax D phenotype. On the other hand, none of the characterized CMVs infecting other species encode vMIA, and MEFs are permissive for murine CMV (which does not have any vMIA homologs) and may be of Bax͞Bak coD phenotype.
Previously, we reported (17) that the cell-death-suppressing activity of vMIA, like that of Bcl-2, is limited to type II cells (45) and that vMIA was not functional in type I BJAB cells. Our current data suggest that the death-suppressing activity of vMIA is limited even further to only the Bax D subset of type II cells. In this property, vMIA differs from Bcl-2 and Bcl-x L , which suppress both Bax-and Bak-mediated apoptosis (8) , which fits the current models for their mechanisms of action (Fig. 4) . However, we should take into consideration that the division of cells into type I and type II has been defined only for death-receptor-mediated apoptosis, and it remains to be established whether apoptosis induced by other types of stimuli, such as viral infection, various cytotoxic drugs, or ␥-irradiation, in type I cells proceeds through activation of caspase-8 and then through the direct caspase-8-mediated activation of Bid, or through a caspase-8-independent up-regulation of a BH3-only death factor. It may well be that vMIA (and Bcl-2) suppresses apoptosis triggered by such stimuli in type I cells as well. Similarly, the involvement of Bax and Bak in the mitochondrial apoptotic pathway triggered in response to various stimuli may also differ depending on the nature of the stimulus (42) .
Taken together, our data support the model in which vMIA and Bcl-2͞Bcl-x L block mitochondrial membrane permeabilization by targeting the opposite components of the tBid͞Bax pair: vMIA inactivates Bax, whereas Bcl-2͞Bcl-x L inactivates tBid. The mechanism of cell death suppression by vMIA is also distinct from that by E1B19K and humanin, two antiapoptotic proteins that directly target Bax. E1B19K inhibits Bax-and Bak-mediated apoptosis, has affinity for Bak and for tBid-activated Bax, and blocks relocation of Bax from the cytoplasm to mitochondria (46, 47) . Humanin appears to suppress apoptosis by binding Bax and preventing its activation and relocation to mitochondria (48) .
CMV is a major cause of morbidity and mortality in immunocompromised individuals, such as organ transplant recipients and patients with AIDS, and a major cause of congenital disease during pregnancy. Our finding that vMIA binds Bax establishes a rationale for the development of screening assays to search for anti-CMV drugs that target and inactivate vMIA.
